knowledge -WSS

knowledge

author：fashion 2025-10-02 07:33:37 - browse：6947

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Health Care Service Corp to buy Cigna Medicare Advantage plans

hotspot

WSS

Physicians and social media: If you see something, say something?

Stop the failed accountable care organization experiment

FTC sues over Novant Health acquisition of two N.C. hospitals

Medicare drug price negotiation legal challenge met with skepticism

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Merck CEO won’t testify in Senate, citing no expertise in drug prices

explore

knowledge

leisure time

Bright Health sells Medicare Advantage business to Molina

SCOTUS questions limit to govt efforts to fight misinformation

Wildfire smoke exposes gaps in outdoor worker protections

Intermittent fasting comes with a heart risk? Not so fast

State Dept. review finds Biden bears some blame for Afghanistan failures

Why you shouldn’t ask, “What country has the best health care?”

Duchenne breakthrough therapy leaves behind pioneering families

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Novavax promises a turnaround & Lilly roils the obesity market

Leading voice in opioid treatment defends methadone clinic system

hotspot

Biogen walks away from Aduhelm, years after polarizing approval

Syphilis numbers in the United States reach record heights

App could help diagnose ear infections more accurately — and at home

SCOTUS questions limit to govt efforts to fight misinformation

https://cbu01.alicdn.com/img/ibank/2016/886/916/3332619688_1907380036.220x220xz.jpg

AstraZeneca to buy developer of next

focus

hotspot

hotspot

leisure time